Between January 2020 and April 2021, 20 patients with a high IFN-γ score in the tumor and 20 patients with a low IFN-γ score in the tumor were enrolled and randomized to arms A or B and C or D, respectively (Fig. 2 and Fig. S2). The gene discussed is IFNG; the disease is neoplasm.